Skip to main content

Table 7 Comparison of breast cancers in patients with CHEK2 mutations to cancers in patients without CHEK2 mutations

From: Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin

Feature   CHEK2-positive cases CHEK2-negative cases p
   (n = 252) (n = 2976)  
Age in years (mean)   44.2 44.3 0.7
Age group 20–30 3.6% (9/252) 1.7% (52/2976) 0.07
  31–40 15.9% (40/252) 17.2% (512/2976) 0.7
  41–50 80.5% (203/252) 81% (2412/2976) 0.9
Histology ductal G1–2 grade 29.3% (54/186) 26.9% (622/2315) 0.6
  ductal G3 grade 10.7% (20/186) 12.7% (294/2315) 0.5
  medullary 2.1% (4/186) 4.9% (113/2315) 0.1
  lobular 21.5% (40/186) 15.8% (366/2315) 0.05
  tubulo-lobular 4.3% (8/186) 3.6% (83/2315) 0.8
  DCIS 11.3% (21/186) 7.2% (168/2315) 0.06
  other 4.8% (9/186) 5.1% (118/2315) 1.0
  missing or unknown 16.7% (31/186) 23.8% (551/2315) 0.03
Pre-operative chemotherapy   27.7% (66/238) 24.5% (661/2693) 0.3
Oestrogen receptor positive 65.1% (97/149) 63.7% (1048/1646) 0.8
Tumour size (cm) <1 cm 5.9% (9/152) 11.2% (193/1728) 0.05
  1–2 cm 40.1% (61/152) 45.3% (783/1728) 0.2
  >2 cm 53.9% (82/152) 43.5% (752/1728) 0.01
Lymph nodes positive 45.0% (68/151) 40.1% (722/1777) 0.3
Multicentric   28.7% (41/143) 19.5% (316/1619) 0.01
Bilateral   2.3% (5/215) 3.3% (84/2531) 0.6
Family history positive*   13.8% (31/224) 8.9% (237/2652) 0.02
  1. *family history refers to a first-degree relative of a proband affected with breast cancer
  2. DCIS – intraductal cancer (ductal carcinoma in situ) with microinvasion; p – p-value